Cargando…
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
AIMS/HYPOTHESIS: The Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was a double-blind, randomised, event-driven, treat-to-target prospective trial comparing the cardiovascular safety of in...
Autores principales: | Zinman, Bernard, Marso, Steven P., Poulter, Neil R., Emerson, Scott S., Pieber, Thomas R., Pratley, Richard E., Lange, Martin, Brown-Frandsen, Kirstine, Moses, Alan, Ocampo Francisco, Ann Marie, Barner Lekdorf, Jesper, Kvist, Kajsa, Buse, John B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002963/ https://www.ncbi.nlm.nih.gov/pubmed/28913575 http://dx.doi.org/10.1007/s00125-017-4423-z |
Ejemplares similares
-
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
por: Pieber, Thomas R., et al.
Publicado: (2017) -
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020) -
Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020) -
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
por: Brown‐Frandsen, Kirstine, et al.
Publicado: (2019) -
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
por: Pratley, Richard E., et al.
Publicado: (2019)